4/A//SEC Filing
Haurwitz Rachel E. 4/A
Accession 0001209191-22-028169
CIK 0001619856other
Filed
May 9, 8:00 PM ET
Accepted
May 10, 7:29 PM ET
Size
9.0 KB
Accession
0001209191-22-028169
Insider Transaction Report
Form 4/AAmended
Haurwitz Rachel E.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2022-01-26$2.96/sh+10,000$29,600→ 10,000 total - Exercise/Conversion
Option to purchase Common Stock
2022-01-26−10,000→ 126,350 totalExercise: $2.96Exp: 2023-06-11→ Common Stock (10,000 underlying)
Holdings
- 3,349,395(indirect: By Trust)
Common Stock
Footnotes (4)
- [F1]Due to a rounding error, the exercise price for this stock option was inadvertently originally reported as $2.95 per share on the reporting person's Form 3 filed on July 22, 2021.
- [F2]This Form 4/A is being filed to correct an inadvertent error in the original Form 4 filed January 27, 2022 attributing direct ownership of 3,349,395 shares listed in column 5 to the reporting person. As described in a Form 5 filed on February 9, 2022, on September 27, 2021, these 3,349,395 shares were transferred to a trust for which the reporting person and her spouse serve as a Co-Trustees.
- [F3]Shares are held by The City Canyon Trust Dated May 31, 2021, of which the reporting person is a Co-Trustee with her spouse.
- [F4]1/4th of the shares subject to this option vested on June 12, 2019 and an additional 1/48th of the aggregate number of shares subject to this option have vested or will vest on the corresponding day of each month thereafter until the option is fully vested on June 12, 2022, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
Documents
Issuer
Caribou Biosciences, Inc.
CIK 0001619856
Entity typeother
Related Parties
1- filerCIK 0001670579
Filing Metadata
- Form type
- 4/A
- Filed
- May 9, 8:00 PM ET
- Accepted
- May 10, 7:29 PM ET
- Size
- 9.0 KB